Myeloma UK
Clinical Service Excellence Programme

Menu

Home
CPD & Learning
Library
Resources
News & Events
- News
- Event calendar
- Meeting highlights
- Close
CSEP
About Us
- Contact Us
- Close

Menu back

MNLP – Module 5 – Final assessment

Time limit: 0

Quiz-summary

0 of 20 questions completed

Questions:

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Information

You have already completed the quiz before. Hence you can not start it again.

Quiz is loading…

You must sign in or sign up to start the quiz.

You have to pass the previous Module’s quiz in order to start this quiz:

Results

Quiz complete. Results are being recorded.

Results

0 of 20 questions answered correctly

Your time:

Time has elapsed

You have reached 0 of 0 point(s), (0)

Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)

Categories

Not categorized 0%

Congratulations on completing Final Assessment 5.

Proceed to Final Assessment 6 »

Return to the Module list »

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Answered
Review

Question 1 of 20

1. Question
1 point(s)
Which of the following statements is not true.

The aim of treatment is to:
- A. Prolong survival
- B. Maximise quality of life
- C. Control the myeloma for as long as possible
- D. Reduce the levels of the myeloma as little as possible
- E. Relieve symptoms and reduce complications as much as possible
Correct

Incorrect
Question 2 of 20

2. Question
1 point(s)
Which of the following treatment combinations is not used as induction treatment prior to stem cell transplantation
- A. Cyclophosphamide, thalidomide, dexamethasone
- B. Velcade, thalidomide, dexamethasone
- C. Cyclophosphamide, Velcade dexamethasone
- D. Vincristine, Adriamycin, dexamethasone
- E. Melphalan, prednisolone, thalidomide
Correct

Incorrect
Question 3 of 20

3. Question
1 point(s)
Treatment of myeloma currently takes into account the following factors except for
- A. Age
- B. Presence or absence of symptoms and complications
- C. Patient preference
- D. Cytogenetic profile
- E. Stage of disease
Correct

Incorrect
Question 4 of 20

4. Question
4 point(s)
Several classes of drugs are used to treat myeloma. Can you match the drug to the correct class?
Sort elements
- Immunomodulatory drug
- Alkylating chemotherapy agent
- Corticosteroid
- Proteasome inhibitor
- Thalidomide
- Cyclophosphamide
- Dexamethasone
- Velcade
Correct

Incorrect
Question 5 of 20

5. Question
2 point(s)
Match the correct terms to the following statement
Sort elements
- older and/or less fit myeloma patients
- younger and/or fitter myeloma patients
- Non-intensive treatment is recommended for
- while intensive treatment is recommended for
Correct

Incorrect
Question 6 of 20

6. Question
1 point(s)
Abbreviations are commonly used to describe anti-myeloma treatment combinations. What drugs make up PAD?
- A. Pomalidomide, Adriamycin, dexamethasone
- B. Prednisolone, Adriamycin, dexamethasone
- C. Velcade, Adriamycin, dexamethasone
- D. Velcade and dexamethasone
- E. Pomalidomide and dexamethasone
Correct

Incorrect
Question 7 of 20

7. Question
1 point(s)
Complete the following statement

It is necessary for all patients who are prescribed thalidomide to be registered on a risk management programme because
- A. It is common practice with all cancer treatments
- B. It is a teratogen
- C. It is a tetracycline
- D. None of the above
- E. All of the above
Correct

Incorrect
Question 8 of 20

8. Question
1 point(s)
Which of the following is not considered to be a contraindication to thalidomide
- A. Creatinine clearance > 30 ml/min
- B. Creatinine clearance < 30ml/min
- C. Thrombophilia or a history of severe thrombosis
- D. Pregnancy or patients of child-bearing age unable to follow or comply with the required contraceptive measures
- E. Allergic to thalidomide
Correct

Incorrect
Question 9 of 20

9. Question
1 point(s)
Intensive treatment involves
- A. High-dose chemotherapy given as a one off
- B. High-dose chemotherapy given weekly until disease progression
- C. High-dose chemotherapy followed by stem cell transplantation
- D. High-dose chemotherapy followed by consolidation treatment
- E. High-dose chemotherapy followed by maintenance treatment
Correct

Incorrect
Question 10 of 20

10. Question
1 point(s)
The approval of Velcade as a treatment for relapsed myeloma was based on which pivotal trial?
- A. Myeloma XI
- B. Myeloma IX
- C. MUK one
- D. APEX
- E. MM-009
Correct

Incorrect
Question 11 of 20

11. Question
1 point(s)
The favoured route of Velcade administration is
- A. Oral
- B. Subcutaneous
- C. Intramuscular
- D. Intravenous
- E. Intrathecal
Correct

Incorrect
Question 12 of 20

12. Question
1 point(s)
Revlimid is licensed for use in combination with which drug for relapsed myeloma patients?
- A. Prednisolone
- B. Dexamethasone
- C. Cyclophosphamide
- D. Melphalan
- E. Adriamycin
Correct

Incorrect
Question 13 of 20

13. Question
4 point(s)
Type in the words short-term, long-term, sustaining, maximising to complete the following definitions.
- Maintenance treatment is treatment administered with the aim of control of the myeloma.
  
  Consolidation treatment is treatment administered with the aim of the depth of response to a previous treatment.
Correct

Incorrect
Question 14 of 20

14. Question
1 point(s)
Assertion: High-dose chemotherapy and stem cell transplantation is used to treat myeloma

BECAUSE

Reason: Conventional chemotherapy is unable to provide a deep and durable response for many patients
- A. True True – reason correctly explains assertion
- B. True True – both statements are true but the reason does not explain the assertion
- C. True False
- D. False True
- E. False False
Correct

Incorrect
Question 15 of 20

15. Question
1 point(s)
Assertion: Remission periods generally lengthen with subsequent treatments

BECAUSE

Reason: Acquired drug resistance is the reason why patients ultimately become refractory to treatment
- A. True True – reason correctly explains assertion
- B. True True – both statements are true but the reason does not explain the assertion
- C. True False
- D. False True
- E. False False
Correct

Incorrect
Question 16 of 20

16. Question
1 point(s)
Assertion: Revlimid is successfully used to treat myeloma

BECAUSE

Reason: Revlimid has immunomodulatory effects
- A. True True – reason correctly explains assertion
- B. True True – both statements are true but the reason does not explain the assertion
- C. True False
- D. False True
- E. False False
Correct

Incorrect
Question 17 of 20

17. Question
1 point(s)
Dexamethasone can cause changes in blood sugar levels and induce diabetes in some myeloma patients
- A. True
- B. False
Correct

Incorrect
Question 18 of 20

18. Question
1 point(s)
Lenalidomide (Revlimid®) maintenance treatment has proven to be much better tolerated than thalidomide
- A. True
- B. False
Correct

Incorrect
Question 19 of 20

19. Question
1 point(s)
Any treatment combination incorporating an immunomodulatory drug with a steroid increases the risk of
- Peripheral neuropathy
- Constipation
- Hair loss
- Venous thromboembolism
- Nausea and sickness
Correct

Incorrect
Question 20 of 20

20. Question
1 point(s)
What does NICE stand for?
- A. National Institute for Clinical Excellence
- B. National Institute for Chemotherapy Excellence
- C. National Institute for Health and Care Excellence
- D. National Institute for Health and Clinical Excellence
- E. Northern Institute for Clinical Excellence
Correct

Incorrect

Bottom menu

Charity No. SC 026116
Myeloma UK
22 Logie Mill
Beaverbank Business Park
Edinburgh
EH7 4HG

MNLP – Module 5 – Final assessment